Sign In
Buy URGN
$38.24
-2.85 (-6.94%)
At Close: Jul 31, 2026
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
08:00am, Thursday, 06'th Nov 2025
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the U
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
08:00am, Tuesday, 04'th Nov 2025
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Thursday
03:02am, Tuesday, 04'th Nov 2025
Urogen Pharma (NASDAQ: URGN - Get Free Report) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.70
UroGen: Expect Rough Patch Before Strong Recovery In 2026
08:36am, Sunday, 02'nd Nov 2025
UroGen Pharma is revisited after a previous Strong Buy rating, with UroGen having increased ~95% since then. The article reflects on UroGen's RTGel technology, which supports JELMYTO and ZUSDURI, its
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
08:00am, Thursday, 30'th Oct 2025
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 29'th Oct 2025
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
08:00am, Monday, 27'th Oct 2025
PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Monday, 08'th Sep 2025
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma to Present at Upcoming Investor Conferences
08:00am, Thursday, 21'st Aug 2025
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Piper starts 'underestimated' UroGen Pharma with an Overweight
06:27am, Tuesday, 19'th Aug 2025
As previously reported, Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target. Investors are starting to gain more confidence in the Zusduri launch, but the
UroGen Pharma: Targeting Profits In 2027
03:34pm, Monday, 18'th Aug 2025
UroGen Pharma Ltd. recently secured FDA approval for Zusduri, its second commercial product, which is expected to significantly boost future revenues. Analysts remain bullish, with multiple Buy rating
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
03:05am, Saturday, 09'th Aug 2025
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Christopher Degnan - Chief Financial Officer David Lin - Chief Commercial Officer Eli
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
10:16am, Thursday, 07'th Aug 2025
Urogen Pharma (URGN) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.91 per share a year ago.
